4//SEC Filing
Kjellson Nina S 4
Accession 0000950170-24-124184
CIK 0001863127other
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 4:43 PM ET
Size
11.2 KB
Accession
0000950170-24-124184
Insider Transaction Report
Form 4
Kjellson Nina S
Director
Transactions
- Sale
Common Stock
2024-11-06$17.18/sh−5,635$96,784→ 451,629 total(indirect: By 2020+ Co-Investment L.P. - Series 7) - Sale
Common Stock
2024-11-07$17.32/sh−19,720$341,513→ 3,735,871 total(indirect: By Canaan XI L.P.) - Sale
Common Stock
2024-11-07$17.32/sh−2,371$41,061→ 449,258 total(indirect: By 2020+ Co-Investment L.P. - Series 7) - Sale
Common Stock
2024-11-06$17.18/sh−46,856$804,775→ 3,755,591 total(indirect: By Canaan XI L.P.)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
- [F3]The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Tyra Biosciences, Inc.
CIK 0001863127
Entity typeother
Related Parties
1- filerCIK 0001381980
Filing Metadata
- Form type
- 4
- Filed
- Nov 7, 7:00 PM ET
- Accepted
- Nov 8, 4:43 PM ET
- Size
- 11.2 KB